Deficiency in mevalonate kinase (MVK) causes systemic inflammation. However, the molecular mechanisms linking the mevalonate pathway to inflammation remain obscure. Geranylgeranyl pyrophosphate, a non-sterol intermediate of the mevalonate pathway, is the substrate for protein geranylgeranylation, a protein post-translational modification that is catalyzed by protein geranylgeranyl transferase I (GGTase I). Pyrin is an innate immune sensor that forms an active inflammasome in response to bacterial toxins. Mutations in MEFV (encoding human PYRIN) result in autoinflammatory familial Mediterranean fever syndrome. We found that protein geranylgeranylation enabled Toll-like receptor (TLR)-induced activation of phosphatidylinositol-3-OH kinase (PI(3)K) by promoting the interaction between the small GTPase Kras and the PI(3)K catalytic subunit p110d. Macrophages that were deficient in GGTase I or p110d exhibited constitutive release of interleukin 1b that was dependent on MEFV but independent of the NLRP3, AIM2 and NLRC4 inflammasomes. In the absence of protein geranylgeranylation, compromised PI(3)K activity allows an unchecked TLR-induced inflammatory responses and constitutive activation of the Pyrin inflammasome.
The mevalonate pathway is a fundamental metabolic pathway responsible for cholesterol biosynthesis that has been successfully targeted by statins, which are inhibitors of the 3-hydroxyl-3-methylglutaryl co-enzyme A reductase (HMGCR), in the treatment of hypercholesterolemia. MVK catalyzes the phosphorylation of mevalonate, a crucial step in the mevalonate pathway 1 . Patients carrying loss-of-function mutations in MVK develop inflammatory phenotypes, including recurrent fever, lymphadenopathy, arthritis and elevated inflammatory cytokines in serum. There are two types of MVK deficiency, the less-severe hyperimmunoglobuline D and periodic fever syndrome (HIDS) and the more severe mevalonate aciduria (MA) 2 . The autoinflammatory phenotypes in patients with mevalonate-kinase deficiency (MKD) suggest that the mevalonate pathway critically regulates the inflammatory response, but the underlying molecular mechanisms remain unknown.
Unlike the conventional inflammatory cytokines, interleukin 1β (IL-1β) and the closely related interleukin-18 (IL-18) are atypical in that they are synthesized as inactive precursors in the cytosol 3 . Maturation and release of these cytokines depends on inflammasomes, large protein complexes that consist of a receptor, the adaptor protein ASC and pro-inflammatory caspases 4 . Dysregulation of inflammasome activity and hyper-production of IL-1β are associated with autoinflammatory diseases 5 . One such disease, familial Mediterranean fever (FMF), is caused by mutations in MEFV, which encodes human PYRIN, an innate immune sensor that forms a caspase-1-activating inflammasome in response to bacterial toxins 6 . These FMF-associated mutant forms of PYRIN confer a heightened sensitivity to PYRIN inflammasome, leading to hyper-production of IL-1β and autoinflammation.
The PI(3)Ks also have important roles in the regulation of the innate immune response 7, 8 . Kinases downstream of PI(3)Ks, such as Akt1 (ref. 9) , glycogen synthase kinase-3β (Gsk3β) 10 and the mechanistic Target of Rapamycin (mTOR) 11 , inhibit TLR-induced pro-inflammatory cytokine production through post-translational modification of transcription factors such as NF-κB, AP-1, CREB and STAT3 (refs. 12,13) . PI(3)K activity is regulated by multiple factors, including Ras and Rho family small GTPases 14 .
In addition to cholesterols, the mevalonate pathway also synthesizes other intermediates, such as the non-sterol isoprenoid geranylgeranyl pyrophosphate (GGPP). GGPP can be used as substrate for protein post-translational modifications; namely, protein geranylgeranylation 15 . Protein geranylgeranylation is catalyzed by GGTase I. Macrophages that are deficient in the β-subunit of GGTase I (protein geranylgeranyl transferase-1 β subunit; encoded by Pggt1b) are hyper-activated by lipopolysaccharide (LPS). Mice with conditional deficiency in Pggt1b in myeloid cells also develop inflammatory arthritis spontaneously 16 . These observations suggest that protein geranylgeranylation controls the innate immune response; however, the underlying molecular mechanisms remain unclear.
We uncovered an unanticipated link between the mevalonate pathway and TLR-induced PI(3)K activation. Through protein geranylgeranylation, the mevalonate pathway enabled TLR-induced PI(3)K activation by promoting the interaction between the Ras family small GTPase Kras and the PI(3)K catalytic subunit p110δ. Inhibition of the mevalonate pathway decreased the production of GGPP and limited protein geranylgeranylation, thereby impairing PI(3)K activation. Impaired PI(3)K activation resulted in hyper-inflammatory conditions, including hyper-production of pro-inflammatory cytokines, elevated expression of Pyrin protein and spontaneous activation of the Pyrin inflammasome.
RESULTS

Differential regulation of cytokine production by Pggt1b
To define the role of protein geranylgeranylation in the regulation of TLR-induced production of cytokines, we used enzyme-linked immunosorbent assay (ELISA) to assess the response of Pggt1b-deficient bone-marrow-derived macrophages (BMDMs) to stimulation by ligands of TLRs. Stimulation of Pggt1b-deficient macrophages with ligands to TLR4 (LPS), TLR9 (CpG), TLR2 (Pam3CSK4) and TLR7 (R848) led to potent upregulation of pro-inflammatory cytokines such as IL-1β, TNF, IL-6 and IL-12 in comparison with wild-type control BMDMs ( Fig. 1a-d) . Concurrently, the production of anti-inflammatory IL-10, as well as type I interferon and the chemokine RANTES, was suppressed in Pggt1b-deficient macrophages ( Fig. 1e-g) . Notably, Pggt1b-deficient BMDMs exhibited decreased production of both pro-and anti-inflammatory cytokines following stimulation with the TLR3 ligand poly(I:C). Quantitative RT-PCR revealed that the altered cytokine production in Pggt1b-deficient cells was caused by altered levels of transcription ( Supplementary Fig. 1a ), suggesting that protein geranylgeranylation differentially regulates cytokine gene expression at the transcriptional level. In addition to the commonly studied cytokines, we also observed enhanced production of granulocyte growth factor G-CSF and neutrophil chemotactic factor KC(Cxcl1), as well as dampened production of chemokines MCP-1, MIP1β and MIP1α, in a multiplex-cytokine assay ( Supplementary  Fig. 1b ). Pggt1b fl/fl Lyz2-Cre mice had elevated frequencies of granulocytes in their circulation ( Fig. 2a,b) . To further investigate the physiological relevance of altered cytokine production caused by Pggt1b deficiency in vivo, we challenged mice with LPS at a lethal dose of 30 mg per kg of body weight. Within 12 h of LPS challenge, 80% of Pggt1b fl/fl Lyz2-Cre mice died, whereas none of the Pggt1b fl/+ Lyz2-Cre mice died (Fig. 2c) . The increased susceptibility of mice to endotoxic shock correlated with higher LPS-induced serum concentrations of the pro-inflammatory cytokines IL-1β, TNF and IL-6 ( Fig. 2d-f ). Together these data suggest that Pggt1b differentially regulate TLRinduced inflammatory cytokine production.
IKK and MAPK activation are not affected by Pggt1b deficiency
The altered cytokine production in Pggt1b-deficient macrophages prompted us to evaluate the activation of the IKK, MAPK and TBK1 signaling pathways downstream of TLRs 17 . We stimulated wild-type and Pggt1b-deficient macrophages with a low dose of LPS (10 ng/ml) and evaluated the activation of IKKβ, MAPK and TBK1 by immunoblot analysis with phosphorylation-specific antibodies. Activation of IKKβ, JNK, p38, Erk and TBK1 was not enhanced or suppressed in Pggt1b-deficient macrophages compared with their activation in wildtype control cells ( Supplementary Fig. 2a,b ). Endocytosis of TLR4 induced by LPS stimulation was not impaired or enhanced in Pggt1bdeficient macrophages either ( Supplementary Fig. 2c ), suggesting that there is no TLR trafficking defect 18 . We conclude that the altered cytokine profile in Pggt1b-deficient macrophages is not a result of altered activation of IKK, MAPK, TBK1 or TLR endocytosis.
Compromised PI(3)K activation in the absence of Pggt1b
The cytokine production profile that we observed in Pggt1b-deficient macrophages is markedly similar to that in myeloid cells deficient in PI(3)K-Akt signaling components, such as p85α 19, 20 , p110δ 18 , mTOR 11 and Akt1 (ref. 9), or treated with Gsk3β inhibitors 10 . We speculated that protein geranylgeranylation regulates TLR-induced cytokine production by controlling PI(3)K-Akt activation. Pggt1bdeficient macrophages displayed substantially lower constitutive Akt phosphorylation. When Pggt1b-deficient BMDMs were stimulated with LPS, phosphorylation of Akt at both Ser473 and Thr308 was severely compromised compared with wild-type control cells ( Fig. 3a) . Consistent with compromised Akt activation, phosphorylation of Gsk3β at Ser9 was also severely diminished in Pggt1b-deficient cells A r t i c l e s ( Fig. 3b) . Gsk3β is phospho-inactivated by Akt at Ser9 (ref. 21) . Thus, decreased Ser9 phosphorylation correlates with higher Gsk3β kinase activity. Indeed, immunoblot analysis revealed that phosphorylation of the c-Jun Thr239 and RelA Ser536, two well-established Gsk3β substrates 21 (Supplementary Fig. 3a) , was enhanced in Pggt1bdeficient BMDMs compared with wild-type control cells ( Fig. 3b) . Phosphorylation of Thr389 on p70S6K kinase, a direct substrate of mTORC1, was greatly decreased in Pggt1b-deficient cells ( Fig. 3c) . Accordingly, pre-treatment of Pggt1b-deficient macrophages with a Gsk3β inhibitor (SB216763) partially reversed the phenotypes ( Supplementary Fig. 3b-f ). On the basis of these results, we conclude that Pggt1b controls the PI(3)K-Akt-Gsk3β and mTOR kinase cascade downstream of TLR in macrophages.
Pggt1b deficiency is a phenocopy of Pik3cd −/− BMDMs Class IA PI(3)Ks are heterodimers composed of a regulatory subunit (p85α or p85β) and a catalytic subunit (p110α, p110β or p110δ). Although p110α and p110β are ubiquitously expressed, p110δ expression is enriched in hematopoietic cells and appears to be more important in immune cell signaling 22 . It has been reported that p110δ is involved in balancing the production of pro-versus antiinflammatory cytokines and protects mice from endotoxic shock 18 . We found that LPS stimulation alone induced robust IL-1β release in p110δ-deficient (Pik3cd −/− ) BMDMs (Fig. 4a) . Pik3cd −/− BMDMs also displayed enhanced production of IL-12, TNF and IL-6 and suppressed production of IFN-β ( Fig. 4b-e ). These phenotypes exactly mirrored those observed in Pggt1b-deficient BMDMs (Fig. 1a) . Together, these results suggest that protein geranylgeranylation regulates TLR signaling, most probably through p110δ of the class IA PI(3)K family.
Constitutively active p110δ 'rescues' Pggt1b deficiency
To further confirm that protein geranylgeranylation controls cytokine production by regulating p110δ activation, we infected wild-type or Pggt1b-deficient BMDMs with retrovirus harboring cDNAs encoding wild-type p110δ, Pggt1b or a constitutively active form of p110δ (E1121K) 23 . Expression of E1121K, but not wild-type p110δ, completely abrogated LPS-induced IL-1β release and restored the production of A r t i c l e s TNF, IL-12 and IL-10 to the levels observed in wild-type BMDMs; we found the same result in Pggt1b-deficient BMDMs reconstituted with wild-type Pggt1b (Fig. 4f) . These findings further confirm that Pggt1b controls p110δ activity downstream of TLR.
Pggt1b controls the interaction between Kras and p110d
To investigate how protein geranylgeranylation regulates PI(3)K activity, we focused on proteins that can be geranylgeranylated. None of the PI(3)K family members carry a CAAX motif, which is essential for prenylation. However, the catalytic subunits of the class IA PI (3) npg A r t i c l e s 1.305; Nras, 0.003; Kras, 1.816). This is consistent with a published report indicating that human KRAS can be geranylgeranylated in the presence of farnesylation inhibitors, whereas HRAS can only be farnesylated 26 . In vivo labeling of primary BMDMs using 3 H-geranylgeranyl pyrophosphate revealed that murine Ras proteins can be geranylgeranylated in macrophages under physiological conditions and that this process depends on Pggt1b (Fig. 5a) .
To evaluate which murine Ras proteins mediate PI(3)K activation, we knocked down the expression of Kras, Nras or Hras in primary BMDMs using small interfering RNA (siRNA). Knocking down the expression of Kras, but not Hras or Nras, in primary BMDMs markedly decreased Akt phosphorylation following LPS stimulation ( Fig. 5b-d) . We therefore conclude that Kras, but not Hras or Nras, is essential for TLR-induced PI(3)K activation.
In the carboxy-terminal CAAX motifs of prenylated proteins, C represents cysteine, A represents aliphatic amino acid and X can be any amino acid. The carboxyl terminal (X) directs either farnesylation or geranylgeranylation. GGTase I prefers substrates with a carboxyl terminal leucine (CAAL) 27 . To investigate how prenylation regulates Ras GTPases interaction with p110δ, we constructed wild-type and CAAL mutant forms of Ras-encoding cDNAs (wild type: Hras, CVLS; Nras, CVLM; Kras, CTVM; CAAL mutant: Hras, CVLL; Nras, CVIL; Kras, CVIL) into retroviral vectors. The Prenylation Suite predicted these CAAL mutant Ras GTPases to be more likely to be geranylgeranylated (data not shown). Stable cell lines were established by transduction of immortalized wild-type BMDMs with retroviral vectors harboring cDNAs encoding either wild-type or the CAAL mutant form of Ras proteins. Immunoprecipitation of endogenous p110δ revealed that interaction of Kras-CVIL (the CAAL (geranylgeranylated) form) with p110δ was markedly enhanced in comparison with the wild-type Kras (CTVM) protein. In the same setting of the experiments, the interaction between Nras or Hras with p110δ was adversely affected by the increased potential of geranylgeranylation (Fig. 5e) . This result suggests that protein geranylgeranylation specifically increases the interaction between Kras and p110δ.
Given that Ras-PI(3)K interaction is essential for optimal PI(3)K activation 14 , we hypothesized that protein geranylgeranylation regulates the Kras-p110δ interaction. Immunoprecipitation of p110δ from cell lysate of LPS-stimulated BMDMs revealed that Kras proteins were constitutively associated with p110δ in resting wild-type cells. This was consistent with the higher basal level of Akt phosphorylation in wild-type cells (Fig. 3a) . Following LPS stimulation, Ras proteins dissociated from p110δ (Fig. 5f) . However, in Pggt1b-deficient BMDMs, this constitutive association was markedly decreased. 
A r t i c l e s
Although LPS stimulation could induce transient interaction between Kras proteins and p110δ, this interaction was much weaker and was not sustained for more than 10 min (Fig. 5f) . We did not see altered interaction between Kras and the class IA catalytic subunits p110α and p110β. These observations suggest that the interaction between Kras and p110δ is regulated by protein geranylgeranylation.
Pyrin inflammasome mediates IL-1b release in Pggt1b −/− BMDMs The success of treating patients with MKD with anti-interleukin-1 agents such as the recombinant IL-1 receptor antagonist anakinra 28 suggests that IL-1 and inflammasomes are important in the pathogenesis of MKD. Stimulation of Pggt1b-deficient macrophages with LPS alone resulted in robust IL-1β maturation and release, whereas the same stimulation did not induce robust IL-1β production in wildtype cells (Figs. 1a and 6a) . The LPS-induced processing and release of IL-1β in Pggt1b-deficient BMDMs began 2 h after LPS stimulation and peaked at 6 h (Supplementary Fig. 4a ). In addition to LPS, CpG (TLR9), Pam3CSK4 (TLR2) and R848 (TLR7), but not poly(I:C), induced spontaneous IL-1β maturation and release in Pggt1bdeficient BMDMs (Supplementary Fig. 4b ), suggesting that TLR3 signaling is differentially regulated by protein geranylgeranylation than other TLRs. Re-expression of Pggt1b in Pggt1b-deficient BMDMs completely reversed the spontaneous IL-1β maturation following LPS stimulation (Supplementary Fig. 4c,d) .
Further analysis using BMDMs from compound transgenic strains of mice revealed that IL-1β maturation and release was abrogated in Pggt1b −/− Casp1 −/− or Pggt1b −/− Pycard −/− (Pycard encodes ASC) BMDMs stimulated with LPS, but not in Pggt1b −/− Nlrp3 −/− cells (Supplementary Fig. 5a-c) . These results indicate that TLR-induced spontaneous IL-1β maturation in Pggt1b-deficient BMDMs is mediated by caspase-1 and ASC, but not by NLRP3. Given that caspase-11mediated IL-1β processing also depends on NLRP3 (ref. 29 ), we ruled out the possibility of a role for caspase-11.
Pyrin has been defined as an innate immune sensor that forms a caspase-1-activating inflammasome in response to bacteria toxins 6 . Mutations in the human PYRIN-encoding MEFV gene result in FMF 5 . Using an siRNA approach, we found that knocking down the expression of Mefv, but not Aim2 or Nlrc4, resulted in a marked inhibition of IL-1β release and caspase-1 processing in Pggt1b-deficient BMDMs (Fig. 6b,c) , suggesting that the Pyrin inflammasome mediates LPS-induced IL-1β secretion in Pggt1b-deficient BMDMs. Similar to Pggt1b-deficient cells, stimulation of Pik3cd −/− BMDMs with LPS alone also induced robust IL-1β production ( Figs. 4a and 6d) . The maturation of IL-1β in Pik3cd −/− BMDMs was accompanied by the release of the caspase-1 p20 subunit, an indication of the activation of capase-1 inflammasomes (Fig. 6d) . Notably, re-expression of a constitutively active form of p110δ (E1121K) completely rescued the IL-1β-producing phenotype in Pggt1b-deficient BMDMs (Figs. 4f  and 6e) . Furthermore, an siRNA approach revealed that knocking down just the expression of Mefv severely inhibited LPS-induced inflammasome activation in Pik3cd −/− BMDMs (Fig. 6f) . Taken together, these data indicate that GGTase I controls Pyrin inflammasome activation through the PI(3)K-p110δ signaling pathway.
Pggt1b and p110d control Mefv expression
We found that Mefv mRNA expression was barely detectable in wildtype BMDMs without stimulation, and its expression was induced by LPS treatment. In the Pggt1b-or p110δ-deficient BMDMs, the basal level of Mefv mRNA expression was higher than that of wild-type controls. Notably, Mefv expression was hyper-induced in both Pggt1bdeficient BMDMs and p110δ-deficient cells (Fig. 6g,h) . Consistent with that, Pyrin protein expression was much higher in Pggt1bdeficient BMDMs (Fig. 6i) . It is known that expression of Mefv is driven by the NF-κB subunit RelA 30 and that the kinase Gsk3β promotes the transactivation activity of RelA via phosphorylation of RelA 10 . We found rampant Gsk3β activity and enhanced phosphorylation of RelA in Pggt1b-deficient BMDMs (Fig. 3b) . Taken together, our results support the notion that enhanced NF-κB RelA transactivational activity drives hyper-expression of Mefv that may contribute to TLR-induced IL-1β release in Pggt1b-or p110δdeficient BMDMs.
Enhanced production of IL-1b in PBMCs from patients with HIDS To mimic the disease conditions of patients with HIDS, we used healthy human peripheral blood mononuclear cells (PBMCs) treated with simvastatin, an inhibitor of HMGCR, to inhibit the mevalonate pathway 1 . When we treated healthy PBMCs with LPS, we detected only minimal amounts of IL-1β maturation in the supernatant. Robust IL-1β production only occurred when PBMCs from healthy donors were pre-treated with simvastatin to inhibit the mevalonate pathway (Fig. 7a) . However, when PBMCs from patients with HIDS were stimulated with LPS alone, a fraction of the patients showed npg A r t i c l e s hyper-production of IL-1β without inhibition of the mevalonate pathway by simvastatin (patients 1, 2 and 3); in a few other cases, there was spontaneous production of IL-1β without any stimulation, which may have been caused by pathogen infection (patient 4, 5 and 6) ( Fig. 7a) . Gene-expression profiling revealed that healthy PBMCs, when treated with LPS and simvastatin, displayed enhanced production of proinflammatory cytokines compared with cells stimulated with LPS alone (Fig. 7b) . Accordingly, when healthy PBMCs were treated with simvastatin and LPS, phosphorylation of Akt Ser473 was severely compromised (Fig. 7c) . These results corroborate our findings in the mouse model of protein geranylgeranylation deficiency and highlight how the mevalonate pathway controls the innate immune response by controlling PI(3)K-Akt signaling by protein geranylgeranylation in both mouse and human cells (Supplementary Fig. 6 ).
DISCUSSION
The crucial role of the PI(3)K-Akt-Gsk3β and mTOR kinase cascade in the regulation of TLR-induced cytokine production has emerged as an important aspect of innate immune signal transduction 8, 12, 21 32 . We found decreased production of IFN-β in Pggt1b-deficient BMDMs stimulated with LPS and poly(I:C). Pggt1b-deficient BMDMs displayed attenuated PI(3)K activation following LPS and poly(I:C) (data not shown) stimulation. This is consistent with published data that PI(3)K positively regulates IFN-β production through inactivation of Gsk3β [33] [34] [35] . It is also of note that, unlike ligands to TLR2, 4, 7 and 9, TLR3 ligand poly (I:C) stimulation induced TNF and IL-6 were decreased in Pggt1bdeficient BMDMs. Poly(I:C) also failed to activate inflammasome in the absence of Pggt1b. These results indicate that protein geranylgeranylation differentially regulates MyD88-dependent and MyD88-independent signaling pathways; the precise underlying mechanism merits further investigation.
Published studies have shown that binding of Ras proteins to class IA PI(3)K RBD is essential for both physiological and pathological functions of PI(3)Ks 24, 36 . However, the manner in which the interaction between Ras and PI(3)K contributes to the TLR-induced innate immune response is not completely understood. In the early 1990s, the finding that farnesylation of KRAS is essential for its oncogenic function galvanized tremendous enthusiasm in developing FTase inhibitors to treat human cancers with KRAS mutations. Unfortunately, the FTase inhibitors showed poor efficacy in clinical trials 37 , as KRAS can also be geranylgeranylated when FTase I is inhibited [38] [39] [40] . FTase I and GGTase I are both hetero-dimmers that share an α subunit and have distinct, but highly homologous, β subunits 15 . Our data revealed that murine Ras proteins are geranylgeranylated by GGTase I in wild-type mouse BMDMs. In earlier studies, knockout of the β subunit of FTase I (Fntb) was shown to block farnesylation of proteins, but had no effect on Kras signaling, membrane targeting or function, and had no effect on cytokine production in myeloid cells 16 . Moreover, the absence of Fntb in macrophages did not induce any inflammatory phenotypes in vivo. Mice deficient in both Pggt1b and Fntb in macrophages display phenotypes that are indistinguishable from that of the Pggt1b single-knockout mouse 16 . Taken together, our data suggested that protein geranylgeranylation, but not farnesylation, positively regulates a Kras and p110δ interaction that is essential for the activation of p110δ and its downstream kinase cascades.
It has been shown that deficiency in p110δ in dendritic cells causes a defect in intracellular trafficking of TLR4 following LPS stimulation 18 . However, we found no such defect in Pggt1b-deficient BMDMs. Such discrepancies can be attributed to either differences in the cell types examined (macrophage versus DCs) or in the genetic backgrounds of the mouse strains used. Although we saw enhanced production of pro-inflammatory cytokines in healthy PBMCs treated with LPS and simvastatin, the production of INF-β and IL-10 was not consistent with that observed in Pggt1b-deficient mouse BMDMs. We believe the discrepancy is caused by the difference of the experimental settings. The phenotype observed in Pggt1b-deficient mouse BMDMs was caused solely by the deficiency in protein geranylgeranylation, whereas simvastatin inhibition of the mevalonate pathway results in the shortage of not only GGPP, but also a variety of other intermediates downstream of HMGCR in the metabolic pathway. The effect of the shortage of those intermediates on inflammatory responses remains to be investigated, but could explain why simvastatin inhibition does not completely recapitulate the phenotypes caused by protein geranylgeranylation deficiency.
We observed a markedly increased basal level of IκBα in Pggt1bdeficient cells. IκBα itself is a target of NF-κB. Rampant Gsk3β kinase activity caused an increased level of NF-κB/RelA phosphorylation as a result of Pggt1b deficiency leading to an inhibited constitutive level of Akt activity. This in turn increased the transactivational activity of RelA to drive the expression of IκBα gene in resting Pggt1b-deficient cells.
The PI(3)K-Akt-Gsk3β and mTOR pathway have pivotal roles in controlling a variety of essential cellular functions such as cell growth, survival, differentiation and metabolism 41 . Dysregulation of PI(3)K activity is implicated in a myriad of human diseases, particularly cancer and diabetes. Our data implicate protein geranylgeranylation in the regulation of TLR-induced p110δ activation in myeloid cells. It is possible that the same mechanisms exist in other tissues and cell types to control class IA PI(3)Ks downstream of growth factor receptors. Thus, our findings may provide clues for manipulating the mevalonate pathway for the intervention of diseases such as cancer, diabetes and aging.
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